Skip to main content
Article thumbnail
Location of Repository

Time to full publication of studies of anti-cancer medicines for breast cancer, and the potential for publication bias: a short systematic review

By A. Takeda, E. Loveman, P. Harris, D. Hartwell and K. Welch


Objectives: To identify the expected delay between publication of conference abstracts and full publication of results from trials of new anti-cancer agents for breast cancer and to identify whether there are any apparent biases in publication and reporting.<br/><br/>Data sources: Major electronic databases were searched to identify randomised controlled trials (RCTs) of the selected interventions for the treatment of breast cancer.<br/><br/>Review methods: A systematic review was conducted according to standard methods. Data were extracted from the included studies using a predesigned and piloted data extraction template.<br/><br/>Results: Six anti-cancer treatments for breast cancer were included in the review: docetaxel, paclitaxel, trastuzumab, gemcitabine, lapatinib and bevacizumab. The literature searches generated 1556 references, from which 71 publications were retrieved and screened for inclusion. Screening identified 41 publications of 18 RCTs with at least one arm of treatment meeting the inclusion criteria for the review. Of the 18 included RCTs, only four publications (from three RCTs) reported the same outcomes in both an abstract and a full publication. Time between the abstract and full publication was 5 months in two cases, 7 months in one case and 19 months in one case (overall mean delay = 9 months). Eleven trials were identified that have not currently published in a full publication the data presented in an abstract or conference proceeding. The duration between publication of the abstracts and the end of August 2007 varied from 3 months to 38 months (mean delay 16.5 months). The longest delays in publication were for trials investigating gemcitabine (38 months) or bevacizumab (33 months). Observational analysis of the published and unpublished trials did not indicate any particular biases in terms of whether positive results were more likely to be fully published than non-significant ones.<br/><br/>Conclusions: It was surprising that only three of the 18 relevant RCTs had one or more full papers that reported the same outcome measures (and stage of analysis) as an earlier conference abstract. However, a limitation of this review is the small number of studies included. With a larger sample size than that in the present report, investigation into the effect of publication delay on decision-making might be feasible. Future research should include extension of this work to other anticancer drugs and investigation into the reasons for lengthy delays to full publication noted for some trials

Topics: R1, RC0254, RZ
Year: 2008
OAI identifier:
Provided by: e-Prints Soton
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • (external link)
  • Suggested articles


    1. (2001). 1 Clinical and cost-effectiveness of donepezil, rivastigmine and galantamine for Alzheimer’s disease: a rapid and systematic
    2. (2004). 24 paclitaxel (T) as frontline therapy for metastatic breast cancer (MBC): first report of overall survival.
    3. (2006). A phase III study of SU011248 in combination with paclitaxel versus bevacizumab with paclitaxel in the first-line advanced disease setting in patients having breast cancer. Study type: phase III open-label RCT. Sample size: 740. Start date:
    4. (2007). A quality-adjusted time without symptoms or toxicity (Q-TWiST) analysis comparing lapatinib plus capecitabine compared to capecitabine for metastatic breast cancer (MBC). doi
    5. (2005). A randomized phase III trial of paclitaxel versus paclitaxel plus bevacizumab as first-line therapy for locally recurrent or metastatic breast cancer: a trial coordinated by the Eastern Cooperative Oncology Group (E2100). Breast Cancer Res Treat doi
    6. (2008). A review by
    7. (2002). A study of the methods used to select review criteria for clinical audit. By Hearnshaw
    8. (2008). A systematic review and economic model of switching from nonglycopeptide to glycopeptide antibiotic prophylaxis for surgery. By Cranny
    9. (2008). All rights reserved. 51 No. 21 Systematic reviews of the effectiveness of day care for people with severe mental disorders: (1) Acute day hospital versus admission; (2) Vocational rehabilitation; (3) Day hospital versus outpatient care. By doi
    10. (2008). All rights reserved. 57 No. 23 A systematic review to examine the impact of psycho-educational interventions on health outcomes and costs in adults and children with difficult
    11. (2008). Bevacizumab: no previous NICE guidance (continued)Health Technology Assessment
    12. (2008). Burls A.Health Technology Assessment doi
    13. (2006). End date: not reported. Status: currently recruiting patients. Funding: Genentech. Funding amount: not reported.
    14. (2008). et al.Health Technology Assessment
    15. (2002). factorial phase III RCT. Sample size: 4646. Start date:
    16. Gemcitabine and split-dose paclitaxel or docetaxel in metastatic breast cancer: a randomised phase II study. doi
    17. (2004). Gemcitabine plus paclitaxel (GT) versus paclitaxel (T) as first-line treatment for anthracycline pre-treated metastatic breast cancer (MBC): quality of life (QoL) and pain palliation results from the global phase III study. doi
    18. (2006). Health-related quality of life among patients with metastatic breast cancer receiving paclitaxel versus paclitaxel plus bevacizumab: results from the Eastern Cooperative Oncology Group (ECOG) study E2100. Breast Cancer Res Treat doi
    19. (2007). Lapatinib (L) plus capecitabine (C) in HER2+ advanced breast cancer (ABC): genomic and updated efficacy data. doi
    20. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. doi
    21. (2006). Lapatinib plus capecitabine shows superior efficacy compared to capecitabine alone in patients with ErbB2 positive advanced or metastatic breast cancer initial biomarker data. Abstract no. 2, San Antonio Breast Cancer Symposium,
    22. (2008). Metronomic chemotherapy with and without bevacizumab for advanced breast cancer: a randomized phase II study. Breast Cancer Res Treat 2005;94:S6.Health Technology Assessment
    23. (2008). Midlands Centre for Adverse Drug Reactions, City Hospital NHS Trust, Birmingham Professor Paul Glasziou, Professor of Evidence-Based Medicine,
    24. (2006). multicentre, single-arm, open-label, expanded access study. Sample size: approximately eight. Start date:
    25. (2003). No. 1 How important are comprehensive literature searches and the assessment of trial quality in systematic reviews? Empirical study.
    26. (2007). No. 1 Pemetrexed disodium for the treatment of malignant pleural mesothelioma: a systematic review and economic
    27. (2005). No. 1 Randomised controlled multiple treatment comparison to provide a costeffectiveness rationale for the selection of antimicrobial therapy in acne.
    28. (2005). Paclitaxel: from STA (early breast cancer)Appendix 2 34 Trastuzumab TABLE 13 Trastuzumab: from STA (early breast cancer) Publication details Number of participants Key outcomes Decisions by
    29. Phase II trial of neoadjuvant docetaxel with or without bevacizumab in patients with locally advanced breast cancer. doi
    30. (2005). phase III multicentre RCT. Sample size: 1200. Start date:
    31. (2002). Phase III trial of capecitabine (Xeloda (R)) plus bevacizumab (Avastin (TM)) versus capecitabine alone in women with metastatic breast cancer (MBC) previously treated with an anthracycline and a taxane. Breast Cancer Res Treat
    32. Randomized phase II trial of three gemcitabine (GEM)-taxane combinations in metastatic breast cancer (MBC).
    33. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. doi
    34. (2006). The clinical and cost-effectiveness of donepezil, rivastigmine, galantamine and memantine for Alzheimer’s
    35. Toxicity results and early outcome data on a randomized phase II study of docetaxel +/– bevacizumab for locally advanced, unresectable breast cancer.
    36. (2006). Trastuzumab: from STA (early breast cancer) (continued) TABLE 14 Trastuzumab: new studies Publication details Number of participants Key outcomes Decisions by
    37. (2004). What is the best imaging strategy for acute stroke? By

    To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.